GDMT improves heart failure mortality and morbidity in HFrEF patients, but only shows modest improvement in exercise capacity.1
1. Lewis G et al. Circ Heart Fail. 2022 May; 15(5):510-524;
2. Abraham WT, Zile MR et al. JACC: Heart Failure 2015 June; 3(6):487-496;
3. Zile MR, et al. J Am Coll Cardiol 2020; 76:1-13;
4. Heidenreich PA, et al. 2022 Circulation. 2022;145:e895–e1032; Class I and Class IIa recommendations
Barostim works by electrically stimulating carotid baroreceptors which increases baroreflex sensitivity, rebalances the autonomic nervous system and improves heart failure symptoms.
Watch the animation
Baroreflex Activation Therapy is delivered by the Barostim NEO, an implantable pulse generator (IPG) designed to deliver continuous electrical stimulation to carotid baroreceptors.
The Barostim System comprises the Barostim NEO IPG, the Carotid Sinus Lead and a simple, intuitive Programmer.
The Barostim System is implanted in a safe surgical procedure where the Carotid Sinus Lead is sutured to the carotid sinus and the Barostim NEO IPG is inserted in a standard device pocket.
Procedures are typically performed on an outpatient basis.
The system contains no hardware in the heart or vasculature.